Addition of TUS to standard of care VEN+AZA creates a well-tolerated and mutation agnostic frontline triple drug therapy for newly diagnosed AML Addition of TUS to standard of care VEN+AZA creates ...

BioNTech kauft CureVac für $1,25 Mrd., stärkt Onkologiegeschäft Unternehmen befanden sich im Wettlauf um Corona-Impfstoff Deal vereint komplementäre Kompetenzen im Krebs-Bereich ...

DVRd therapy significantly improves MRD negativity and PFS, showing potential as a frontline treatment for NDMM patients who are transplant-ineligible or deferred. The CEPHEUS trial highlights ...

The oral presentation at EHA included updated safety, complete remission, minimal residual disease (MRD) assessments, and longer duration of follow-up: Title: TUSCANY Study of Safety and Efficacy of ...

SAN DIEGO and TORONTO, June 12, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company, today ...

The oral presentation at EHA included updated safety, complete remission, minimal residual disease (MRD) assessments, and longer duration of follow-up: Title: TUSCANY Study of Safety and Efficacy ...

"These presentations and the recent incorporation of ctDNA-MRD testing in B-cell lymphoma clinical guidelines give us confidence as we prepare to launch in the clinical market in 2026 and ...

"NPM1 transcript levels detected the rising MRD on repeated samples, and chemotherapy was stopped. After two doses of the IMP, given post-lymphodepletion, the patient has now achieved a complete ...

These may include reports on clinical trials where cfDNA epigenomics is being used for early cancer detection, minimal residual disease (MRD) detection, or monitoring therapeutic responses in real ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...